Phenotypic and Genotypic Characterisation of a Large, Multicentre Italian Cohort of 46, XY DSD Patients

Condition46, XY DSD
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
AgeUp to 18
SponsorIRCCS Azienda Ospedaliero-Universitaria di Bologna

About this trial

Observational exploratory study of a cohort of pediatric and adolescent patients diagnosed with DSD karyotype 46,XY, a rare congenital clinical condition characterized by a disharmonic development between chromosomal sex, gonadal sex and/or phenotypic sex.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

Karyotype 46,XY DSD;

Genital ambiguity signs assessed on the basis of clinical phenotype and EMS/EGS for karyotype 46,XY DSD;

Age < 18 years at diagnosis of 46,XY DSD;

Patients referred to the IRCCS Azienda Ospedaliero-Universitaria di Bologna since 01/01/1991 or to other participating centres since 01/01/2000;

Disqualifiers

None

Trial population

Patients aged \< 18 years at diagnosis of 46,XY DSD who referred to the IRCCS Azienda Ospedaliero-Universitaria di Bologna, Italy, since 01/01/1991 or to other participating italian centres since 01/01/2000.

Trial design

Design model

Cohort

Time perspective

Other

Treatments tested in this trial

Not listed

Trial groups

No trial groups listed

Trial outcomes

Primary outcomes

1

Prevalence of 46,XY DSD patients

number of 46,XY DSD patients referred to partecipating centres during the reporting period

Time frame
4 years after the start of enrollment
2

Sex

sex assigned at birth, and current sex (M/F)

Time frame
at baseline
3

EMS/EGS (External Masculinization Score ed ExternalGenital Score)

presence/absence of micropenis, bifid scrotum, urethral meatus position, testicles position, genital tubercle, mullerian residues

Time frame
at baseline
4

Age of onset of genital ambiguity signs

years, months

Time frame
at baseline

Secondary outcomes

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.